NYSERT
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NYSERT (NYSERT).
NYSERT is a fixed-dose combination of nystatin and sertaconazole. Nystatin, a polyene antifungal, binds to ergosterol in fungal cell membranes, disrupting permeability and causing cell death. Sertaconazole, an azole antifungal, inhibits lanosterol 14α-demethylase (CYP51), blocking ergosterol synthesis and accumulation of toxic methylsterols. Synergistic action provides broad-spectrum antifungal activity against Candida spp. and dermatophytes.
| Metabolism | Nystatin is not absorbed systemically; metabolized in the gut via unknown pathways, excreted unchanged in feces. Sertaconazole: Primarily hepatic metabolism via CYP3A4 to inactive metabolites; minimal systemic absorption (<1%). |
| Excretion | Primarily hepatic metabolism (CYP3A4) followed by biliary excretion of metabolites; ~60% fecal, ~30% renal (as metabolites), <5% unchanged in urine. |
| Half-life | Terminal elimination half-life approximately 20-25 hours in healthy adults; prolonged in hepatic impairment (up to 40 hours) and in elderly patients. |
| Protein binding | ~99% bound to serum proteins, primarily albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd approximately 7-10 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Oral bioavailability is ~60% due to first-pass metabolism; not available parenterally. |
| Onset of Action | Oral: onset within 1-2 hours; peak antipsychotic effect occurs after 2-4 weeks of daily dosing. |
| Duration of Action | Duration of action is approximately 24 hours with once-daily dosing; steady-state achieved within 5-7 days. |
| Molecular Weight | 315.37 |
10 mg orally once daily at bedtime, with or without food.
| Dosage form | SUPPOSITORY |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (eGFR ≥30 mL/min). Severe renal impairment (eGFR <30 mL/min) not studied; use with caution. No pharmacokinetic data for dialysis. |
| Liver impairment | Child-Pugh Class A or B: no dose adjustment. Child-Pugh Class C: not recommended due to lack of data. |
| Pediatric use | Not approved for pediatric patients (safety and efficacy not established). |
| Geriatric use | No specific dose adjustment recommended; monitor for adverse effects due to age-related decreased clearance. Starting dose of 5 mg may be considered for elderly patients with frailty or comorbidities. |
| 1st trimester | No adequate studies in pregnant women; animal studies show fetal abnormalities at high doses. Use only if benefit outweighs risk. |
| 2nd trimester | Risk of fetal harm cannot be excluded; consider alternative therapies. |
| 3rd trimester | May cause adverse effects on fetal development; avoid during third trimester unless clearly needed. |
Clinical note
Comprehensive clinical and safety monograph for NYSERT (NYSERT).
| Placental transfer | Expected to cross placenta due to low molecular weight and lipophilicity; human data limited. |
| Breastfeeding | Excreted into breast milk in low amounts; monitor infant for potential adverse effects such as diarrhea or skin rash. Use with caution. |
| Lactation Rating |
■ FDA Black Box Warning
None
| Serious Effects |
Hypersensitivity to NYSERT or any excipientsSevere hepatic impairment
| Precautions | Hypersensitivity reactions (urticaria, angioedema) possible; discontinue if irritation occurs; avoid intravaginal use in patients with known hypersensitivity to any azole or polyene antifungals; not for oral, ophthalmic, or systemic use; may weaken latex condoms and diaphragms (avoid use within 72 hours of product use); pregnancy category C (use only if clearly needed); breastfeeding women: use caution due to possible infant exposure. |
| Food/Dietary | No known food interactions with topical nystatin. For oral suspension, avoid food or drink for 30 minutes after administration to maximize contact time. |
Loading safety data…
| L2 (Safer) |
| Teratogenic Risk | FDA Pregnancy Category C. First trimester: No adequate human studies; animal studies show fetal abnormalities at high doses. Second and third trimesters: Risk of preterm labor, low birth weight, and neonatal adaptation syndrome (e.g., respiratory depression, jitteriness) with chronic use. Avoid use unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal vital signs, neurologic status, and signs of respiratory depression. Fetal assessment includes non-stress test and biophysical profile if used near term for chronic pain. For epidural use, standard maternal and fetal monitoring during labor. |
| Fertility Effects | NYSERT may inhibit uterine contractions; no direct effect on fertility. Chronic use may alter reproductive hormone levels, but clinical significance unknown. |
| Clinical Pearls | NYSERT (nystatin) is a polyene antifungal used topically for Candida infections. Do not use for systemic fungal infections. Monitor for local irritation or sensitization. In oral thrush, ensure contact time by holding suspension in mouth before swallowing. For vaginal use, continue through menstruation. For diaper rash, combine with barrier cream and frequent diaper changes. |
| Patient Advice | Use exactly as directed for the full duration, even if symptoms improve. · For oral suspension: swish in mouth for several minutes before swallowing; do not eat or drink for 30 minutes after. · For topical cream: apply thin layer to affected area; avoid contact with eyes. · For vaginal tablets: insert high into vagina at bedtime; use sanitary pad to protect clothing. · Stop use and consult doctor if rash, irritation, or allergic reaction occurs. · Keep out of reach of children; do not use if allergic to nystatin or any ingredient. |